Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - COGENTIX MEDICAL INC /DE/ | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 1, 2016
COGENTIX MEDICAL, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-20970
|
13-3430173
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
5420 Feltl Road
Minnetonka, Minnesota
|
55343
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(952) 426-6140
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02. | Results of Operations and Financial Condition. |
On February 2, 2016, Cogentix Medical, Inc. (the “Company”) issued a press release providing certain preliminary financial results for the fiscal quarter ended December 31, 2015. A copy of the press release is attached hereto as Exhibit 99.1.
The Company is furnishing the information contained in this report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 1, 2016, the Board of Directors (the “Board”) of the Company approved the appointment of the Company’s current President and Chief Executive Officer (Principal Executive Officer), Robert C. Kill, as the Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of the Company effective as of January 28, 2016, which is the effective date of the resignation of Brett Reynolds as the Company’s Senior Vice President, Chief Financial Officer and Corporate Secretary.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No.
|
Description
|
||
|
99.1
|
Press Release of Cogentix Medical, Inc. dated February 2, 2016 (furnished herewith)
|
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: February 3, 2016
|
COGENTIX MEDICAL, INC.
|
||
|
By:
|
/s/ Robert C. Kill
|
||
|
Name:
|
Robert C. Kill
|
||
|
Title:
|
President, Chief Executive Officer
|
||
|
and Corporate Secretary
|
|||
2
COGENTIX MEDICAL, INC.
CURRENT REPORT ON FORM 8-K
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
Method of Filing
|
||
|
Press Release of Cogentix Medical, Inc. dated February 2, 2016.
|
Furnished electronically
|
3